Andrew Brenner, MD, PhD

“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.

Andrew Brenner, MD, PhD, stated that rhenium obisbemeda elicited similar results in leptomeningeal disease as it did in recurrent glioma.

Patients with recurrent glioblastoma who had an absorbed dose of greater than 100 Gy with rhenium obisbemeda had a median overall survival of 17 months.

According to Andrew Brenner, MD, PhD, rhenium obisbemeda can be detected via SPECT imaging and aids in the care of patients with glioblastoma.

The panel closes their discussion by musing on the future of HER2 mBC treatments.

A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.

The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.

Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.

Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.